Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-02-06
2007-02-06
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S043000, C514S045000
Reexamination Certificate
active
11208046
ABSTRACT:
Compositions and methods are provided for prevention and clinical treatment of various forms of graft-versus-host disease (GVHD) by using inhibitors of adenosine deaminase (ADA). In particular, various formulations and dosing regimens of ADA inhibitors such as pentostatin are provided for the treatment of all forms of GVHD, especially steroid-refractory acute and chronic GVHD.
REFERENCES:
patent: 5635156 (1997-06-01), Ildstad
patent: 5800539 (1998-09-01), Waller
patent: 5876692 (1999-03-01), Ildstad
patent: 5916910 (1999-06-01), Lai
patent: 6174873 (2001-01-01), Wrenn
patent: 6258357 (2001-07-01), Spaner
Trotta et al. Cancer Research, 1981, vol. 41, pp. 2189-2196.
“Pentostatin effective as preparative regimen for kidney transplant”,Expert Review of Anticancer Therapy, (2001), 1(4):508.
Abe, Y. et al., “Eradication of virus-infected T-cell in a case of adult T-cell leukemia/lymphoma by nonmyeloblative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin”, Case Report,International Journal of Hematology, (Jul. 2002), 76(1):91-93.
Akpek, G. Graft-Versus-Host Disease (GVHD) An Evidence-Based Management Guidelines.Turk J Haematol. 2003; 20(3): 123-142.
Alcindor, T. et al., “Engraftment and immunoligic effects a novel less myeloablative allogeneic transplant conditioning regimen of continuous infusion pentostatin, photopheresis, and low dose TBI”,PROC. Blood, (2000), 96(11):327a, abst 5160.
Appelbaum, F., “Allogeneic Stem-Cell Transplantation for Hematological Malignancies”, l ed.Medical Management of Hematological Malignant Diseases, ed. E. Freireich. vol. 1. 1998, New York: Marceil Dekker. 403-419.
Arai, S. et al., “Management of graft-versus-host disease”,Blood Reviews(2000) 14:190-204.
Armitage, J., “Bone Marrow Transplantation”,The New England Journal of Medicine, (1994). 330(12):827-838.
Bagasra, O. et al., “Adenosine-deaminase-associated immunodeficiency. I. Differential sensitivities of lymphocyte subpopulations exposed to 2-deoxycoformycin in vivo”,Clinical&Experimental Immunology, (1992), 88(3):383-388.
Bayer, R. et al., “Pentostatin based non-myeloablative conditioning regimen in patients with high-risk hematologic malignancy”,Proc of ASH, (2000), 96(11):327, abst 5163.
Beatty, P. et al., “Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies”,Transplantation, (Feb. 1991), 51(2):443-447.
Bociek, G.R. et al., Nonmyeloablative allogeneic stem cell transplantation (NST) for lymphoid maignancies using pentostatin/low-dose total body irradiation,BB&MT, (Feb. 2004), 10(2), Supplement 1, p. 27.
Bolanos-Meade, J. et al., “Pentostatin in steroid-refractory acute graft-versus-host disease”,Journal of Clinical Oncology, (Apr. 20, 2005), 23(12):2661-2668.
Catovsky, D. “Clinical experience with 2′-deoxycoformycin”,Hematology&Cell Therapy, (1996), 38(S2):S103-S107.
Catovsky, D. et al., “Long term results with 2′deoxycoformycin in hairy cell leukemia”,Leukemia&Lymphoma, (1994). 14(S1):109-113.
Chan, G. et al., “Decreased acute and chronic graft versus host disease with early full donor engraftment following a pentostatin-based preparative regimen for allogeneic bone marrow translpant in high-risk patients”,Proc Blood, (2001), 98(11):383a, abst 1612.
Chan, G.W. et al., “Age is not associated with adverse outcomes following pentostatin-based preparative regimen for allogeneic bone marrow transplant”,Proc Blood, (2001), 98(11):313b, abst 5011.
Chan, G.W. et al., “Even coagulase negative staphylococcus infections following reduced intensity transplantation are associated with increased transplant complications and poorer overall survival”,BB&MT, (Feb. 2004), 10(2), Supplement 1, p. 11.
Chan, G.W. et al., “Extracorporeal photopheresis, pentostatin and total body irradiation reduced intensity transplantation in relapsed or refractory AML patients: evidence for early graft versus tumor effect with less GVHD”,Blood, (Nov. 16, 2003), 102(11), abst 3265.
Chan, G.W. et al., “Grade 2-4 acute graft-versus-host disease and extensive chronic graft-versus-host disease are associated with significantly decreased survival following reduced intensity allogeneic stem cell transplanatation”,Blood, (Nov. 16, 2004), abst 1246.
Chan, G.W. et al., “MDS patients undergoing a novel reduced intensity allogeneic bone marrow transplant achieves complete remission with less transplant toxicity and graft versus host disease”,Proc. ASH, (2002), abst 2450.
Chan, G.W. et al., “Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease”, (2003), 9:170-176.
Chan, G.W. et al., “Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease”,Biology of Blood and Marrow Transplantation, (2003), 9:753-759.
Chan, G.W. et al., “Targeting host antigen-presenting cells pre-transplant reduces graft versus host disease”,BB&MT, (2002), 8(2).
Chin, K.M. et al., “Favorable outcomes in matched unrelated donor allogeneic stem cell transplantation using a pentostatin/extracorporeal photopheresis based reduced intensity conditioning regimen”,Blood, (Nov. 16, 2003), 102(11), abst 1758.
Cummings, F.J. et al., “Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease”,Journal of Clinical Oncology, (Apr. 1991), 9(4):565-571.
De Lima, M. et al., “Pentostatin, Tacrolimus, and “Mini”-Methotrexate for Graft-Versus-Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled, Randomized Study”,Blood, (Nov. 16, 2004), 104(11), abst 727.
De Lima, M., “GVHD Prophylaxis With Tacrolimus, Mini-methotrexate, and Pentostatin: A Phase I/II Study”, Revitalization of Pentostatin: A New Approach To The Management of GVHD and Allogeneic Transplants. Satellite Symposium at the 2004 Tandem BMT meetings. Feb. 15, 2004; Orlando, Florida.
Dighiero, G. Potential Immunological Action of Purine Nucleoside Analogues,Drugs47 (Suppl. 6) 1994. pp. 57-62.
Epstein, J., et al. Prevention of Graft-Versus-Host Disease in Allogeneic Bone Marrow Transplantation by PreTreatment With 2′-Deoxycoformycin.International Society for Experimental Hematology. (1986). pp. 845-849.
Ferrara, J., “Cytokine Inhibitors and Graft-versus-Host Disease”,Annals New York Academy of Sciences, (Dec. 29, 1995), 770:227-236.
Foss, F. et al., “Novel pentostatin/extracorporeal photopheresis based allogeneic conditioning regimen for high risk non-Hogkin's lymphoma”,Annals of Oncology, vol. 13, Supp. 2, p. 167, Abst 597.
Foss, F. et al., “Novel pentostatin/extracorporeal photopheresis reduced intensity conditioning regimen: results in relapsed/refractory NHL”,Proc. ASH, (2002) abst 413.
Foss, F. et al., “Reduced-Intensity Conditioning for Allogeneic Transplantation”, Revitalization of Pentostatin: A New Approach To The Management of GVHD and Allogeneic Transplants. Satellite Symposium at the 2004 Tandem BMT meetings. Feb. 15, 2004; Orlando, Florida.
Foss, F.M. et al., “Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome”,Journal of Clinical Oncology, (Dec. 1987), 10(12):1907-1913.
Giblett, E.R. et al., “Adenosine-deaminase Deficiency in Two Patients With Severely Impaired Immunity”,Lancet, (Nov. 18, 1972). 2:1067-1069.
Goldberg, Jenna D., et al., “Pentostatin For The Treatment of Chronic Graft-Versus-Host Disease in Children,”Journal of Pediatric Hematology/Oncology(2003, vol. 25, No. 7, pp. 584-588.
Grever M. et al., “Randomized comparison of pentostatin versus i
DiMartino Jorge
Nelson John Tippett
Blank Rome LLP
Lewis Patrick
Mayne Pharma (USA) Inc.
LandOfFree
Composition and method for treating graft-versus-host disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treating graft-versus-host disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating graft-versus-host disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3865774